Drugmakers weren't exactly thrilled last year when Indian ministers nearly quintupled the list of drugs subject to government price controls. As it turns out, neither were bulk buyers of those products. GlaxoSmithKline is now feeling the effects of their discontent, with buyers' protests reportedly hurting the British drugmaker's sales.
Rounding the bend on a likely approval for its hepatitis C drug simeprevir, J&J has acquired an NS5A replication complex inhibitor from GlaxoSmithKline to add to its combination approach to the disease.
Late-phase data has tempered expectations for GlaxoSmithKline's malaria vaccine. Yet while the vaccine prevents fewer cases than hoped and immunity wanes, it still has the potential to cut incidence of disease. Glaxo is readying for a regulatory submission. A malaria vaccine could arrive in 2015.
John Kraus, GSK's medical leader for drisapersen, unveiled more data from the failed study on the exon-skipping technology, which fell short not only on its primary endpoint for improved walking distances in a 6-minute test but also flunked out on three separate secondary endpoints, with the outcomes looking almost identical in each case with a placebo.
Arzerra has not yet been approved anywhere for a first-line use, but the companies believe that new data will boost its chances. It is asking for it to be used in combination with an alkylator-based therapy in patients for which a fludarabine-based therapy is not appropriate.
Scientists at Case Western Reserve University School of Medicine in Cleveland, with colleagues at GlaxoSmithKline and Imperial College London in the U.K., believe they've discovered a way to circumvent that challenge.
As third-quarter earnings season nears, analysts are totting up the potential losses in China. And for GlaxoSmithKline, at the heart of the pharma bribery scandal there, the damage to sales may run up to 30%.
Evidence linking GlaxoSmithKline's swine flu vaccine to narcolepsy has mounted up this year, with new findings from Finland, Sweden and the United Kingdom emerging. Now, having previously knocked back compensation claims, the data has prompted the U.K. government to accept the link.
Friday, the EU's Committee for Medicinal Products for Human Use (CHMP) recommended 11 new drugs for a variety of diseases--the most nods it's given in a single meeting all year.
GlaxoSmithKline got a double dose of good news today about its respiratory drug Breo Ellipta, known as Relvar Ellipta in other markets. Regulators in Europe recommended the potential blockbuster be approved there for COPD and asthma, while regulators in Japan gave it the OK for asthma.